<p>Systemic Sclerosis (also known as Scleroderma) is a chronic autoimmune disease characterized by the abnormal growth of connective tissue, leading to skin thickening, organ fibrosis, and vascular damage. It can significantly affect the skin, lungs, heart, kidneys, and gastrointestinal system. The disease has a complex and varied clinical presentation, and its cause is not fully understood, though it involves both genetic and environmental factors. There is a need for more effective treatments as the current therapies primarily focus on symptom management and slowing disease progression.</p>
<h2><strong>Systemic Sclerosis Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Systemic Sclerosis in the 7MM from 2020 to 2034 includes:</p>
<ul>
<li>Total Systemic Sclerosis Diagnosed Prevalent Cases</li>
<li>Systemic Sclerosis Gender-specific Cases</li>
<li>Systemic Sclerosis Age-specific Cases</li>
<li>Systemic Sclerosis Type-specific Cases</li>
<li>Systemic Sclerosis Severity-specific Cases</li>
<li>Systemic Sclerosis Complication Associated</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/systemic-sclerosis-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Systemic Sclerosis Epidemiology</strong></span></a></h2>
<p>In 2023, the prevalence of Systemic Sclerosis showed distinct trends across the 7MM:</p>
<ul>
<li>In the 7MM, the US accounted for the highest number of Systemic Sclerosis diagnosed prevalent cases, with nearly 102,100 cases.</li>
<li>Among EU4 and the UK, Italy accounted for the highest number of Systemic Sclerosis diagnosed prevalent cases, followed by Germany, while Spain had the least number of diagnosed cases.</li>
<li>Among the subset-specific cases, limited systemic sclerosis was much more prevalent than diffuse systemic sclerosis and systemic sclerosis sine scleroderma.</li>
<li>Among the age-specific cases, the 40&ndash;69 age group accounted for the highest number of cases, representing nearly 62% of the diagnosed cases in the US in 2023.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/systemic-sclerosis-market"><span style="text-decoration: underline;"><strong>Systemic Sclerosis Market</strong></span></a></h2>
<p>The total Systemic Sclerosis Market Size was nearly USD 1,850 million in the 7MM in 2023.</p>
<h2>Systemic Sclerosis Market Drivers</h2>
<ul>
<li>Emerging therapies, such as LUMICEF (BRODALUMAB), BENLYSTA, SAPHNELO, and UPLIZNA, offer the potential to provide more targeted treatments, improving outcomes for Systemic Sclerosis patients.</li>
<li>Increased awareness of the disease and advancements in early diagnostic techniques are helping in earlier identification and better management of Systemic Sclerosis, contributing to market growth.</li>
</ul>
<h2>Systemic Sclerosis Market Barriers</h2>
<ul>
<li>The complexity of the disease, with its heterogeneous clinical presentations, complicates the development and evaluation of therapies, making treatment responses unpredictable.</li>
<li>High treatment costs, along with challenges in achieving widespread access to new therapies, present significant barriers to market expansion, particularly in resource-limited regions.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight"><span style="text-decoration: underline;"><strong>Systemic Sclerosis Emerging Therapies</strong></span></a></h2>
<ul>
<li>LUMICEF (BRODALUMAB)</li>
<li>BENLYSTA</li>
<li>SAPHNELO</li>
<li>UPLIZNA</li>
<li>VIXARELIMAB</li>
<li>AVENCIGUAT</li>
<li>DERSIMELAGON</li>
<li>EFZOFITIMOD</li>
<li>FIPAXALPARANT</li>
<li>VASCULAN</li>
</ul>
<p>And others</p>
<h2><strong>Systemic Sclerosis Key Players</strong></h2>
<ul>
<li>Kyowa Kirin</li>
<li>GSK</li>
<li>AstraZeneca</li>
<li>Amgen (Horizon Therapeutics)</li>
<li>Mitsubishi Tanabe Pharma</li>
<li>Roche (Genentech)</li>
<li>Kiniksa Pharmaceuticals</li>
<li>Boehringer Ingelheim</li>
<li>aTyr Pharma</li>
<li>Kyorin Pharmaceutical</li>
<li>Cumberland Pharmaceuticals</li>
</ul>
<p>And others</p>

Systemic Sclerosis Market

Systemic Sclerosis Market Infographics

Systemic Sclerosis Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.